Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Nykode Therapeutics ASA fell by 43.78m. Cash Flow from Financing totalled 44.59m or 345.60% of revenues. In addition the company used 96.62m for operations while cash from investing totalled 7.04m.
Cash flow per share | -1.17 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 4.87 |
---|---|
Tangible book value per share | 4.87 |
More ▼
Balance sheet in USDView more
Current ratio | 9.28 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0315 |
---|---|
Total debt/total capital | 0.0305 |
More ▼